Articles related to SURGICAL ONCOLOGY

“Patients treated in the Optune Pax arm had a median time to pain progression of 15.2 months compared to 9.1 months.” — PANOVA-3 Trial, FDA Approval Announcement

Statistical models incorporating individual clinical and tumor characteristics showed superior accuracy when validated against standardized clinical trial data compared to retrospective prediction tools.

The modified Johns Hopkins procedure demonstrates how robotic assistance can enhance surgical precision through small incisions, potentially reducing trauma and accelerating recovery in suitable pancreatic cancer patients.

This refined surgical technique for robotic-assisted laparoscopic radical prostatectomy focuses on preserving vital supportive structures while effectively removing the prostate, potentially enhancing post-operative outcomes.

A large-scale randomized controlled trial has identified significant prognostic factors for overall survival (OS) and cancer-specific survival (CSS) in localized prostate cancer, offering new insights into optimizing treatment strategies using surgery and radiotherapy.

In cases of prostate cancer post-aquablation therapy, managing residual tissue and persistent PSA levels poses significant challenges for surgical intervention, as detailed by Dr. Edward M. Schaeffer.